MedTrace Logo

Fasiglifam 25 mg BID vs 50 mg QD

NCT01982253 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-10-07

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.

Conditions

Interventions

DRUG

Fasiglifam

Fasiglifam tablets

DRUG

Placebo to fasiglifam

Fasiglifam placebo-matching tablets

Sponsors & Collaborators

Principal Investigators

  • Senior Medical Director, Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States
  • Bulgaria
  • Poland
  • Romania
  • Slovakia
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01982253 on ClinicalTrials.gov